DigiStorm 2018
Wednesday, March 18, 2026
29.8
C
Bengaluru
Hot topics
Boehringer Ingelheim India focuses on partnerships in NCD management
Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”
Vivek V. Kamath Appointed CEO at PlasmaGen BioSciences
Picture: Deep Bhandari led session at ACG - MedicinMan...
Specially Designed Case Study based Modules for Pharma Marketing Professionals
More than digitalizing your product promotions, the case calls for building and engaging your brand community through digital solutions that create memorable customer experiences.
With the new normal emerging, the traditional Pharma commercial model needs to be relooked by exploring alternative channels of engagement, which offer opportunities to create value for customers.
Company-specific digital adoption workshops to experience how a brand can be promoted using the omnichannel approach with field force involvement.
Inspirational Frontline Leadership
The last issue of 2016, with articles from K. Hariram and Vivek Hattangadi and new authors, Dr. Ashwin Bonde and Diksha Fouzdar. Diksha's article is the highlight of this issue - an in-depth look at how to embed compliance in the very DNA of a pharma company.
The Killer Nexus – What Really Ails Indian Healthcare?
For Every Bottle Of Killer Cough Syrup Doctor Prescribed,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Hot topics
The Rise and Fall of Core Parenterals – India’s IV Fluid Pioneer
Background
Core Healthcare Ltd., popularly known as Core Parenterals, was...
Violence Against Medics – Lessons to Draw from Private Hospitals
One interesting fact: most medical colleges and linked public hospitals in major cities were designed in the British era, with an open ward design. A medical administrator, tongue-in-cheek, put it succinctly: “When these hospitals were designed, nobody would have imagined that doctors will face violence”.
Time for design thinking in public healthcare delivery!
Pharma Marketing in the New Age
Inside this Issue
1. Conference Notes: Pharma Marketing in the New...
Key Challenges Facing Indian Pharma
With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience.
The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.
American Tariffs and The Rise of the Corporate Superpower
From Nation-States to Corporate Titans: How Innovation is Redrawing...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Newsletter
Get important news delivered directly to your inbox and stay connected!